Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
复制标题
DOI：
10.1016/j.antiviral.2005.01.002
复制
发表时间：
2005-06-01
影响因子：
7.6
通讯作者：
Endy, TP
中科院分区：
文献类型：
--
作者：
Paragas, J;Blatt, LM;Endy, TP
研究干扰素alfacon 1治疗SARS冠状病毒（严重急性呼吸综合征-冠状病毒）感染患者的初步数据表明，这种疗法耐受性良好，具有治疗益处。我们在此报告，干扰素alfacon 1，具有有效的抗SARS冠状病毒的体外抗病毒活性。在细胞病变效应保护（CPE）试验中，干扰素alfacon I以剂量依赖性方式抑制CPE的产生，IC 50为0.001 μ g/ml，这是临床可达到的水平。此外，干扰素alfacon 1也表现出显着的抗病毒活性，在产量减少和空斑减少测定。干扰素alfacon 1对SARS-CoV的体外抗病毒活性提示继续评估干扰素alfacon 1作为SARS-CoV感染患者的治疗性治疗。由爱思唯尔公司出版
Preliminary data examining interferon alfacon 1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon 1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon I inhibited the generation of CPE in a dose-dependent manner with an IC50 of 0.001 mu g/ml, a clinically achievable level. Furthermore, interferon alfacon 1 also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon 1 against SARS-CoV suggests continued evaluation of interferon alfacon 1 as a therapeutic treatment for patients infected with SARS-CoV. Published by Elsevier B.V.